Conference Coverage
Conference Coverage
Moderate psoriasis: the new frontier for systemic therapies
UNVEIL trial shows apremilast hits the mark in this population.
Latest News
Guselkumab tops adalimumab for psychiatric comorbidities in psoriasis
Treatment with guselkumab was associated with significantly greater improvements in anxiety and depression.
Latest News
Psoriasis patients face higher risk of alcohol-related death – but lower suicide risk
GENEVA – But a large U.K. study using the same database showed they have a below-average suicide rate.
Conference Coverage
Psoriasis: Biologics bring potential for long-term remission off treatment
GENEVA – The results of an extension study of two pivotal secukinumab studies point to a previously unthinkable concept for severe psoriasis.
Conference Coverage
Pediatric psoriasis carries sharply increased risk of selected autoimmune comorbidities
GENEVA – Unique study captures entire Danish population up to age 18.
Conference Coverage
Genital psoriasis is the worst: Patients sound off
GENEVA – Qualitative study elicits patient perspectives.
Conference Coverage
Ixekizumab has profound impact on genital psoriasis
GENEVA – A swift improvement in the “incredibly debilitating” disease was observed in the randomized trial.
Conference Coverage
Baseline lab data is class specific for biologics to treat psoriasis patients
Maximize success for psoriasis patients on biologics by balancing convenience and cost as well as efficacy and safety.
Conference Coverage
New psoriasis therapies coming of age
Interleukin-23 and interleukin-17 are promising targets in the treatment of moderate to severe plaque psoriasis.
Conference Coverage
Alopecia may be permanent in one in four pediatric HSCT patients
Diffuse hair thinning and psoriasis were among the late dermatologic effects in children who had received a hematopoietic stem cell transplant in...